A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Blinatumomab (Primary) ; Lenalidomide
- Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 09 Oct 2016 Planned number of patients changed from 18 to 36.
- 16 Jun 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2018.